NewAmsterdam Pharma Company NV fell to a 52‑week low of $23.02 on September 9, 2026, trading just above the $23.05 threshold. The move leaves the company with a market capitalization of $2.76 billion and a year‑to‑date decline of about 27%.
The firm has not generated profit over the past twelve months, but its balance sheet remains strong, with cash balances exceeding total debt. A fair‑value assessment from InvestingPro labels the shares as undervalued.
Research houses Stifel and Jefferies each maintained Buy recommendations. Stifel set a price target of $50.00, while Jefferies cited a $45.00 target.
The price pressure follows the failure of Novartis’ HORIZON trial to meet its endpoints, a development Stifel linked to NewAmsterdam’s recent challenges. Stifel also noted that the implications of the HORIZON outcome for NewAmsterdam’s own PREVAIL trial are complex. Jefferies added that forthcoming Novartis data could validate biological mechanisms relevant to NewAmsterdam’s pipeline.
